Extracorporeal Magnetotransduction Therapy (EMTT) for Midfoot Osteoarthritis: A Prospective Pilot Study of Pain and Functional Outcomes
Journal of the American Podiatric Medical Association · 10.07.2026 · 116 (4) · 51
DOI: 10.3390/japma116040051 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Podiatric Medical Association, online erschienen am 10.07.2026. Verfasst von Rohan Charles und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedic Surgery, Mayo Clinic, Rochester, MN 55905, USA. Hauptthemen laut MEDLINE: Osteoarthritis, Magnetic Field Therapy. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Mayo Clinic Hospital, Mayo Clinic’s Orthopedic Research Review Committee (ORRC) Research Support Program, internal department funds.
Abstract (Originalsprache)
Extracorporeal magnetotransduction therapy (EMTT) is a high-energy electromagnetic modality that delivers field strengths of 80–150 mT, effective transduction power > 60 kT/s, and dual-frequency architecture with pulse repetition near 8 Hz and oscillations of 100–300 kHz. This prospective pilot study evaluated pain and functional outcomes in patients with symptomatic midfoot osteoarthritis (OA). Eight patients (13 feet; five bilateral and three unilateral cases) with radiographic Kellgren–Lawrence (KL) grade 3 or 4 midfoot OA received eight EMTT sessions over four weeks. Outcomes were measured at baseline, after the eighth treatment at four weeks, and at 3-month and 6-month follow-up using the 0–10 Visual Analog Scale (VAS) and Foot and Ankle Ability Measure—Activities of Daily Living (FAAM-ADL). VAS demonstrated a significant overall effect of time (F(3,36) = 3.93, p = 0.016), with mean scores decreasing from 4.15 ± 1.63 at baseline to 2.62 ± 1.98 at 3 months and 3.00 ± 2.08 at 6 months. Bonferroni-adjusted baseline-to-follow-up contrasts approached significance at 3 months (p = 0.067) and were not significant at 6 months (p = 0.150). FAAM-ADL improved significantly over time (F(3,30) = 13.76, p < 0.001), increasing from 61.7% ± 9.9% at baseline to 81.8% ± 11.1% at 6 months. No treatment-related adverse events were observed; one participant proceeded to surgery by 6 months and was classified as a treatment failure. These preliminary findings suggest that EMTT is safe and may provide clinically meaningful functional improvement in selected patients with midfoot OA; larger sham-controlled trials are needed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Orthopedic Surgery, Mayo Clinic, Rochester, MN 55905, USA.
ORCID-Profile: Alexander Vlasak, Elizabeth Bondi
Förderung
- Mayo Clinic Hospital
- Mayo Clinic’s Orthopedic Research Review Committee (ORRC) Research Support Program, internal department funds
Zitieren
APA
Charles, R., Vlasak, A., & Bondi, E. (2026). Extracorporeal Magnetotransduction Therapy (EMTT) for Midfoot Osteoarthritis: A Prospective Pilot Study of Pain and Functional Outcomes. Journal of the American Podiatric Medical Association, 116(4), 51. https://doi.org/10.3390/japma116040051
Vancouver
Charles R, Vlasak A, Bondi E. Extracorporeal Magnetotransduction Therapy (EMTT) for Midfoot Osteoarthritis: A Prospective Pilot Study of Pain and Functional Outcomes. Journal of the American Podiatric Medical Association. 2026;116(4):51. doi:10.3390/japma116040051
BibTeX
@article{Charles2026,
author = {Charles, Rohan and Vlasak, Alexander and Bondi, Elizabeth},
title = {Extracorporeal Magnetotransduction Therapy (EMTT) for Midfoot Osteoarthritis: A Prospective Pilot Study of Pain and Functional Outcomes},
journal = {Journal of the American Podiatric Medical Association},
year = {2026},
volume = {116},
number = {4},
pages = {51},
doi = {10.3390/japma116040051}
}
EUVIMED